IN2014MN02293A - - Google Patents
Info
- Publication number
- IN2014MN02293A IN2014MN02293A IN2293MUN2014A IN2014MN02293A IN 2014MN02293 A IN2014MN02293 A IN 2014MN02293A IN 2293MUN2014 A IN2293MUN2014 A IN 2293MUN2014A IN 2014MN02293 A IN2014MN02293 A IN 2014MN02293A
- Authority
- IN
- India
- Prior art keywords
- polypeptides
- scfvs
- antibody
- antibodies
- fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to mono specific and multi specific polypeptides that specifically bind or interact with CD3. These polypeptides can be but are not limited to antibodies fragments thereof scFvs Fabs di scFvs single domain antibodies diabodies dual variable domain binding proteins and polypeptides containing an antibody or antibody fragments. In one embodiment a multi specific polypeptide binds both a T cell receptor complex on T cells and a tumor antigen to induce target dependent T cell cytotoxicity activation and proliferation.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261636557P | 2012-04-20 | 2012-04-20 | |
US201261718635P | 2012-10-25 | 2012-10-25 | |
US201361799849P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/037135 WO2013158856A2 (en) | 2012-04-20 | 2013-04-18 | Cd3 binding polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN02293A true IN2014MN02293A (en) | 2015-08-07 |
Family
ID=49384230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2293MUN2014 IN2014MN02293A (en) | 2012-04-20 | 2013-04-18 |
Country Status (16)
Country | Link |
---|---|
US (1) | US10202452B2 (en) |
EP (1) | EP2839019A4 (en) |
JP (2) | JP6509724B2 (en) |
KR (1) | KR20150004856A (en) |
CN (1) | CN104487587A (en) |
AU (2) | AU2013249267A1 (en) |
BR (1) | BR112014025830A8 (en) |
CA (1) | CA2870545A1 (en) |
HK (2) | HK1207398A1 (en) |
IL (1) | IL235093B (en) |
IN (1) | IN2014MN02293A (en) |
MX (1) | MX366813B (en) |
RU (1) | RU2673153C2 (en) |
SG (2) | SG11201406346SA (en) |
UA (1) | UA119227C2 (en) |
WO (1) | WO2013158856A2 (en) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5620626B2 (en) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | Polypeptide production method by association control |
EP4342995A3 (en) | 2006-03-31 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
TWI807362B (en) | 2010-11-30 | 2023-07-01 | 日商中外製藥股份有限公司 | cell damage-inducing therapeutics |
WO2012145714A2 (en) | 2011-04-22 | 2012-10-26 | Emergent Product Development Seattle, Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
BR112014025830A8 (en) | 2012-04-20 | 2017-10-10 | Emergent Product Dev Seattle | CD3-BINDING POLYPEPTIDES |
JP6534615B2 (en) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | Method for producing polypeptide heteromultimer |
RU2016134256A (en) | 2014-01-24 | 2018-03-05 | Дзе Генри М. Джексон Фаундейшн Фор Дзе Эдвансмент Оф Милитари Медсин, Инк. | ANTIBODIES AGAINST HANDRA VIRUSES AND NICA F Glycoprotein |
WO2016001810A1 (en) | 2014-07-01 | 2016-01-07 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
AU2015292406B2 (en) | 2014-07-25 | 2021-03-11 | Cytomx Therapeutics, Inc | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
MA40764A (en) * | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | THERAPEUTIC AGENT INDUCING CYTOTOXICITY |
BR112017014805A2 (en) | 2015-01-23 | 2018-01-09 | Sanofi | anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies that specifically bind cd3 and / or cd123 |
JP7082484B2 (en) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | Method for Producing Polypeptide Heterogeneous Multimer |
KR102405104B1 (en) | 2015-04-13 | 2022-06-07 | 화이자 인코포레이티드 | Therapeutic antibodies and their uses |
MX2017013298A (en) | 2015-04-13 | 2018-06-19 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen. |
WO2016178996A1 (en) * | 2015-05-01 | 2016-11-10 | The Regents Of The University Of California | Glycan-dependent immunotherapeutic molecules |
AU2016263808B2 (en) | 2015-05-21 | 2019-01-03 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
CN104892765B (en) * | 2015-06-29 | 2018-04-10 | 深圳市国创纳米抗体技术有限公司 | A kind of bispecific antibody of AntiCD3 McAb antigen and Her 2 antigen |
JOP20160154B1 (en) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof |
CN108367004B (en) * | 2015-09-21 | 2022-09-13 | 阿帕特夫研究和发展有限公司 | CD3 binding polypeptides |
US20170096485A1 (en) * | 2015-10-02 | 2017-04-06 | Hoffmann-La Roche Inc. | Bispecific t cell activating antigen binding molecules |
CA2997406A1 (en) | 2015-12-09 | 2017-06-15 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release |
SG10202007025PA (en) | 2016-03-14 | 2020-08-28 | Chugai Pharmaceutical Co Ltd | Cell injury inducing therapeutic drug for use in cancer therapy |
CN107365387B (en) * | 2016-05-12 | 2022-03-15 | 阿思科力(苏州)生物科技有限公司 | Bispecific antigen binding construct, preparation method and application thereof |
US11339225B2 (en) * | 2016-05-12 | 2022-05-24 | Asclepius (Suzhou) Technology Company Group, Co., Ltd. | Bispecific antigen-binding construct and preparation method and use thereof |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
CA3024683A1 (en) * | 2016-05-20 | 2017-11-23 | Harpoon Therapeutics, Inc. | Single chain variable fragment cd3 binding proteins |
KR102530742B1 (en) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | single domain serum albumin binding protein |
EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
CA3059010A1 (en) | 2016-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
CN106117358A (en) * | 2016-06-16 | 2016-11-16 | 中山大学 | AntiCD3 McAb single domain antibody |
CN106117361A (en) * | 2016-06-17 | 2016-11-16 | 中山大学 | AntiCD3 McAb single domain antibody |
CN106117360A (en) * | 2016-06-17 | 2016-11-16 | 中山大学 | AntiCD3 McAb single domain antibody |
CN106084048A (en) * | 2016-06-17 | 2016-11-09 | 中山大学 | AntiCD3 McAb single domain antibody |
CN106146661A (en) * | 2016-06-17 | 2016-11-23 | 中山大学 | AntiCD3 McAb single domain antibody |
CN106117359A (en) * | 2016-06-17 | 2016-11-16 | 中山大学 | AntiCD3 McAb single domain antibody |
CN106084046A (en) * | 2016-06-17 | 2016-11-09 | 中山大学 | AntiCD3 McAb single domain antibody |
CN106084047A (en) * | 2016-06-17 | 2016-11-09 | 中山大学 | AntiCD3 McAb single domain antibody |
CN106084049A (en) * | 2016-06-17 | 2016-11-09 | 中山大学 | AntiCD3 McAb single domain antibody |
BR112018076260A2 (en) | 2016-06-20 | 2019-03-26 | Kymab Limited | antibody or fragment thereof that specifically binds to hpd-11, bispecific antibody or fusion protein, use of an antibody or fragment, method, pharmaceutical composition, modulation method, inhibition method, treatment method, nucleic acid, vector, host and immunocytocin |
EP3471773A4 (en) | 2016-06-21 | 2020-07-08 | Teneobio, Inc. | Cd3 binding antibodies |
CN106146662A (en) * | 2016-07-18 | 2016-11-23 | 中山大学 | AntiCD3 McAb single domain antibody |
CR20190198A (en) * | 2016-09-14 | 2019-10-11 | Teneobio Inc | Cd3 binding antibodies |
WO2018057802A1 (en) * | 2016-09-21 | 2018-03-29 | Aptevo Research And Development Llc | Cd123 binding proteins and related compositions and methods |
AU2017363302A1 (en) | 2016-11-23 | 2019-06-27 | Harpoon Therapeutics, Inc. | PSMA targeting trispecific proteins and methods of use |
KR20210087108A (en) | 2016-11-23 | 2021-07-09 | 하푼 테라퓨틱스, 인크. | Prostate specific membrane antigen binding protein |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
IL268836B2 (en) | 2017-02-24 | 2024-04-01 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
BR112019023856A2 (en) | 2017-05-12 | 2020-06-09 | Harpoon Therapeutics Inc | triespecific proteins targeting msln and methods of use |
EP3621994A4 (en) | 2017-05-12 | 2020-12-30 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
CN110891971B (en) | 2017-06-20 | 2024-01-12 | 特尼奥生物股份有限公司 | Heavy chain-only anti-BCMA antibodies |
CA3068056A1 (en) * | 2017-06-22 | 2018-12-27 | Development Center For Biotechnology | Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in cancer therapy |
WO2019045856A1 (en) * | 2017-08-28 | 2019-03-07 | Systimmune, Inc. | Anti-cd3 antibodies and methods of making and using thereof |
BR112020007249B1 (en) | 2017-10-13 | 2022-11-22 | Harpoon Therapeutics, Inc | B-CELL MATURATION ANTIGEN-BINDING ROUTINE, MULTISPECIFIC BINDING PROTEIN AND USE OF SUCH PROTEINS |
BR112020007196A2 (en) | 2017-10-13 | 2020-12-01 | Harpoon Therapeutics, Inc. | triespecific proteins and methods of use |
JP2021501570A (en) | 2017-10-18 | 2021-01-21 | ノバルティス アーゲー | Compositions and Methods for Selective Proteolysis |
WO2019099639A1 (en) | 2017-11-15 | 2019-05-23 | Navartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
WO2019108900A1 (en) | 2017-11-30 | 2019-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
KR20200104342A (en) | 2017-12-22 | 2020-09-03 | 테네오바이오, 인코포레이티드 | Heavy chain antibody that binds to CD22 |
TW201930591A (en) | 2018-01-08 | 2019-08-01 | 瑞士商諾華公司 | Immune-enhancing RNAs for combination with chimeric antigen receptor therapy |
US20210038659A1 (en) | 2018-01-31 | 2021-02-11 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
EP3752203A1 (en) | 2018-02-13 | 2020-12-23 | Novartis AG | Chimeric antigen receptor therapy in combination with il-15r and il15 |
WO2019160904A1 (en) | 2018-02-15 | 2019-08-22 | Macrogenics, Inc. | Variant cd3-binding domains and their use in combination therapies for the treatment of disease |
CN112533950B (en) * | 2018-06-29 | 2023-03-10 | 多玛医药科技(苏州)有限公司 | anti-CD 3e antibodies and uses thereof |
EP3817770A2 (en) | 2018-07-02 | 2021-05-12 | Amgen Inc. | Anti-steap1 antigen-binding protein |
EP3844267A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
AU2019345052A1 (en) * | 2018-09-19 | 2021-03-18 | FUJIFILM Cellular Dynamics, Inc. | Protein L for activation and expansion of chimeric antigen receptor-modified immune cells |
AU2019346466A1 (en) | 2018-09-25 | 2021-05-20 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
TWI821474B (en) * | 2018-12-07 | 2023-11-11 | 大陸商江蘇恆瑞醫藥股份有限公司 | Cd3 antibody and its pharmaceutical use thereof |
WO2020168555A1 (en) * | 2019-02-22 | 2020-08-27 | 武汉友芝友生物制药有限公司 | Cd3 antigen binding fragment and application thereof |
AU2020229806A1 (en) | 2019-02-25 | 2021-07-29 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
EP3953455A1 (en) | 2019-04-12 | 2022-02-16 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
PE20220575A1 (en) | 2019-06-14 | 2022-04-20 | Teneobio Inc | MULTISPECIFIC HEAVY-CHAIN ANTIBODIES THAT BIND CD22 AND CD3 |
JP2023503163A (en) | 2019-11-26 | 2023-01-26 | ノバルティス アーゲー | Chimeric antigen receptor and uses thereof |
JP2023512454A (en) | 2020-01-13 | 2023-03-27 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Formulations for protein therapy |
CA3164420A1 (en) | 2020-01-13 | 2021-07-22 | Jonathan Clapper | Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components |
CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
KR20220147109A (en) | 2020-02-27 | 2022-11-02 | 노파르티스 아게 | Methods for making chimeric antigen receptor-expressing cells |
WO2021173985A2 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
CA3182697A1 (en) | 2020-05-11 | 2021-11-18 | Janssen Biotech, Inc. | Methods for treating multiple myeloma |
IL298473A (en) | 2020-06-11 | 2023-01-01 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
KR20230058427A (en) | 2020-08-21 | 2023-05-03 | 노파르티스 아게 | Compositions and methods for in vivo generation of CAR expressing cells |
KR20230104617A (en) * | 2020-10-07 | 2023-07-10 | 드렌 바이오, 인크. | Anti-Dectin-1 Antibodies and Methods of Using The Same |
WO2022109611A1 (en) | 2020-11-20 | 2022-05-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
EP4330381A1 (en) | 2021-04-27 | 2024-03-06 | Novartis AG | Viral vector production system |
EP4330277A1 (en) * | 2021-04-28 | 2024-03-06 | NGM Biopharmaceuticals, Inc. | Multimerization of binding molecules having an antibody constant region variant |
KR20240005722A (en) | 2021-04-30 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
TW202243689A (en) | 2021-04-30 | 2022-11-16 | 瑞士商赫孚孟拉羅股份公司 | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
WO2022240865A1 (en) * | 2021-05-11 | 2022-11-17 | Janux Therapeutics, Inc. | Antibodies targeting egfr and cd3 and uses thereof |
EP4341291A1 (en) | 2021-05-21 | 2024-03-27 | Aptevo Research and Development LLC | Dosing regimens for protein therapeutics |
AR126838A1 (en) | 2021-08-20 | 2023-11-22 | Novartis Ag | METHODS FOR PREPARING CELLS THAT EXPRESS CHIMERIC ANTIGEN RECEPTORS |
WO2023180353A1 (en) | 2022-03-23 | 2023-09-28 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
JP2024517042A (en) | 2022-04-13 | 2024-04-19 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Pharmaceutical compositions and methods of use of anti-CD20/anti-CD3 bispecific antibodies |
CN115029318B (en) * | 2022-05-12 | 2022-12-20 | 成都赋智健康科技有限公司 | Mesenchymal stem cell carrying multi-specific antibody gene and pharmaceutical application thereof |
WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US20030108548A1 (en) | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
ES2375561T3 (en) | 1994-01-11 | 2012-03-02 | Dyax Corporation | INHIBITORS OF HUMAN PLASMINE DERIVED FROM KUNITZ DOMAINS AND �? NUCLEIC CIDES CODING THE SAME. |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
WO1998003670A1 (en) | 1996-07-23 | 1998-01-29 | Tanox Pharma B.V. | Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways |
AU2719099A (en) | 1998-01-23 | 1999-08-09 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Multipurpose antibody derivatives |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
WO2002040545A2 (en) * | 2000-11-17 | 2002-05-23 | The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services | Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the fv to lower the isoelectric point |
RU2179862C1 (en) * | 2000-12-26 | 2002-02-27 | Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" | Medicinal preparation to prevent transplant detachment, monoclonal antibody to cd3 antigen of human t-lymphocytes, hybridome and method to treat patients suffering acute transplant detachment reaction following kidney transplantation |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
EP2706116A1 (en) | 2001-01-17 | 2014-03-12 | Emergent Product Development Seattle, LLC | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20040058445A1 (en) | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
US20040044182A1 (en) | 2001-09-17 | 2004-03-04 | Hunt Joan S | Expression, preparation,uses, and sequence of recombinantly-derived soluble hla-g |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
CN100509850C (en) | 2003-05-31 | 2009-07-08 | 麦克罗梅特股份公司 | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
CN1950399A (en) | 2004-02-16 | 2007-04-18 | 麦克罗梅特股份公司 | Less immunogenic binding molecules |
GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
EP3178850B1 (en) | 2005-10-11 | 2021-01-13 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
TW200732350A (en) | 2005-10-21 | 2007-09-01 | Amgen Inc | Methods for generating monovalent IgG |
EP4342995A3 (en) * | 2006-03-31 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
NZ573132A (en) | 2006-06-06 | 2012-05-25 | Glaxo Group Ltd | Administration of anti-cd3 antibodies in the treatment of autoimmune diseases |
WO2007146968A2 (en) | 2006-06-12 | 2007-12-21 | Trubion Pharmaceuticals, Inc. | Single-chain multivalent binding proteins with effector function |
WO2008051448A2 (en) | 2006-10-19 | 2008-05-02 | Tolerx, Inc. | Methods and compositions for efficient removal of protein a from binding molecule preparations |
EP2094302A4 (en) | 2006-12-21 | 2010-12-08 | Macrogenics Inc | Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
US20090148447A1 (en) | 2007-07-06 | 2009-06-11 | Trubion Pharmaceuticals, Inc. | Binding Peptides Having a C-terminally Disposed Specific Binding Domain |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20110177070A1 (en) | 2008-07-02 | 2011-07-21 | Emergent Product Development Seatlle, LLC | TGF-Beta Antagonist Multi-Target Binding Proteins |
MX2011000071A (en) | 2008-07-02 | 2011-05-03 | Emergent Product Dev Seattle | Il6 immunotherapeutics. |
US20110152173A1 (en) | 2008-07-02 | 2011-06-23 | Emergent Product Development Seattle ,LLC | TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINS |
EP2321345A1 (en) | 2008-07-28 | 2011-05-18 | Emergent Product Development Seattle, LLC | Multi-specific binding proteins targeting b cell disorders |
AU2009296297A1 (en) | 2008-09-26 | 2010-04-01 | Roche Glycart Ag | Bispecific anti-EGFR/anti-IGF-1R antibodies |
KR20170091801A (en) | 2008-10-02 | 2017-08-09 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | CD86 Antagonist Multi-Target Binding Proteins |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
US20110217302A1 (en) | 2008-10-10 | 2011-09-08 | Emergent Product Development Seattle, Llc | TCR Complex Immunotherapeutics |
TW201100543A (en) | 2009-05-27 | 2011-01-01 | Hoffmann La Roche | Tri-or tetraspecific antibodies |
EP2516467A2 (en) | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
CN102958942A (en) | 2009-12-29 | 2013-03-06 | 新兴产品开发西雅图有限公司 | Heterodimer binding proteins and uses thereof |
WO2012145714A2 (en) | 2011-04-22 | 2012-10-26 | Emergent Product Development Seattle, Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
KR101308922B1 (en) * | 2012-02-15 | 2013-09-23 | 주식회사 경동나비엔 | Dual venturi for burner |
BR112014025830A8 (en) | 2012-04-20 | 2017-10-10 | Emergent Product Dev Seattle | CD3-BINDING POLYPEPTIDES |
-
2013
- 2013-04-18 BR BR112014025830A patent/BR112014025830A8/en not_active Application Discontinuation
- 2013-04-18 WO PCT/US2013/037135 patent/WO2013158856A2/en active Application Filing
- 2013-04-18 UA UAA201412306A patent/UA119227C2/en unknown
- 2013-04-18 AU AU2013249267A patent/AU2013249267A1/en not_active Abandoned
- 2013-04-18 IN IN2293MUN2014 patent/IN2014MN02293A/en unknown
- 2013-04-18 SG SG11201406346SA patent/SG11201406346SA/en unknown
- 2013-04-18 KR KR20147032216A patent/KR20150004856A/en not_active Application Discontinuation
- 2013-04-18 US US14/395,689 patent/US10202452B2/en not_active Expired - Fee Related
- 2013-04-18 JP JP2015507169A patent/JP6509724B2/en not_active Expired - Fee Related
- 2013-04-18 RU RU2014142166A patent/RU2673153C2/en not_active IP Right Cessation
- 2013-04-18 CA CA2870545A patent/CA2870545A1/en not_active Abandoned
- 2013-04-18 SG SG10201608307WA patent/SG10201608307WA/en unknown
- 2013-04-18 MX MX2014012578A patent/MX366813B/en active IP Right Grant
- 2013-04-18 EP EP13778209.0A patent/EP2839019A4/en not_active Withdrawn
- 2013-04-18 CN CN201380027109.8A patent/CN104487587A/en active Pending
-
2014
- 2014-10-07 IL IL235093A patent/IL235093B/en not_active IP Right Cessation
-
2015
- 2015-08-19 HK HK15108038.0A patent/HK1207398A1/en unknown
- 2015-09-17 HK HK15109147.6A patent/HK1208707A1/en unknown
-
2017
- 2017-09-14 AU AU2017228643A patent/AU2017228643B2/en active Active
-
2018
- 2018-04-18 JP JP2018080199A patent/JP2018138039A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2018138039A (en) | 2018-09-06 |
IL235093B (en) | 2019-09-26 |
IL235093A0 (en) | 2014-12-31 |
MX2014012578A (en) | 2015-05-11 |
HK1208707A1 (en) | 2016-03-11 |
EP2839019A4 (en) | 2016-03-30 |
UA119227C2 (en) | 2019-05-27 |
AU2017228643B2 (en) | 2019-12-05 |
HK1207398A1 (en) | 2016-01-29 |
RU2673153C2 (en) | 2018-11-22 |
US20150232557A1 (en) | 2015-08-20 |
KR20150004856A (en) | 2015-01-13 |
MX366813B (en) | 2019-07-25 |
CA2870545A1 (en) | 2013-10-24 |
SG11201406346SA (en) | 2014-11-27 |
CN104487587A (en) | 2015-04-01 |
JP6509724B2 (en) | 2019-05-08 |
AU2013249267A1 (en) | 2014-10-23 |
BR112014025830A8 (en) | 2017-10-10 |
SG10201608307WA (en) | 2016-11-29 |
RU2014142166A (en) | 2016-06-10 |
WO2013158856A2 (en) | 2013-10-24 |
JP2015521032A (en) | 2015-07-27 |
AU2017228643A1 (en) | 2017-10-05 |
US10202452B2 (en) | 2019-02-12 |
EP2839019A2 (en) | 2015-02-25 |
BR112014025830A2 (en) | 2017-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN02293A (en) | ||
MX2021009151A (en) | Antibodies and chimeric antigen receptors specific for ror1. | |
AU2018260863A1 (en) | Human IgG1 Fc region variants and uses thereof | |
WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
MX2023001356A (en) | Pd1 and/or lag3 binders. | |
PH12018501079A1 (en) | Ctla4 binders | |
NZ706232A (en) | Anti-cd3 antibodies and uses thereof | |
PH12018500520A1 (en) | Cd3 binding polypeptides | |
AR106555A1 (en) | ANTI-IL1RAP ANTIBODIES, BINDING SPECIFIC MOLECULES THAT JOIN IL1RAP AND CD3, AND USES OF THESE | |
WO2012135854A3 (en) | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 | |
MX2017001229A (en) | EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY. | |
MX2014005546A (en) | Albumin binding antibodies and binding fragments thereof. | |
WO2015150526A3 (en) | Cd33 specific chimeric antigen receptors for cancer immunotherapy | |
MX2017001712A (en) | Sirp-alpha immunoglobulin fusion proteins. | |
CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
PH12014502527B1 (en) | St2 antigen binding proteins | |
MX341309B (en) | Anti-il-23 heterodimer specific antibodies. | |
MY176294A (en) | Antibodies comprising chimeric constant domains | |
CO6781527A2 (en) | Antibody type binding proteins with dual variable region that have cross-linkage region orientation | |
MX2021001711A (en) | Engineered bispecific proteins. | |
WO2015069922A3 (en) | Alk antibodies, conjugates, and chimeric antigen receptors, and their use | |
GB201212940D0 (en) | Antibodies to highly conserved targets | |
MX2013013832A (en) | Fc RECEPTOR BINDING PROTEINS. | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
WO2017124001A3 (en) | T cell receptor-like antibodies specific for foxp3-derived peptides |